A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment.

These tumor-specific patterns of expression might partially explain the differences in VTE risk among tumor types. We propose that biomarkers of coagulation fibrinolysis might provide valuable information about the TME in cancer patients.